Production of recombinant Zika virus envelope protein by airlift bioreactor as a new subunit vaccine platform
Appears in Collections:
The Zika Virus (ZIKV) is an emerging arbovirus of great public health concern, particularly in the Americas after its last outbreak in 2015. There are still major challenges regarding disease control, and there is no ZIKV vaccine currently approved for human use. Among many different vaccine platforms currently under study, the recombinant envelope protein from Zika Virus (rEZIKV) constitutes an alternative option for vaccine development and has great potential for monitoring ZIKV infection and antibody response. This study describes a method to obtain a bioactive and functional rEZIKV using an E. coli expression system, with the aid of a 5-L airlift bioreactor and following an automated fast protein liquid chromatography (FPLC) protocol, capable of obtaining high yields of approximately 20 mg of recombinant protein per liter of bacterium cultures. The purified rEZIKV presented preserved antigenicity and immunogenicity. Our results show that the use of an airlift bioreactor for the production of rEZIKV is ideal for establishing protocols and further research on ZIKV vaccines bioprocess, representing a promising system for the production of a ZIKV envelope recombinant protein-based vaccine candidate.
Costa HH.M., Bielavsky M, Orts DJ.B., Astray RM. Production of recombinant Zika virus envelope protein by airlift bioreactor as a new subunit vaccine platform. Int J Mol Sci. 2023 Sep; 24(18):13955. doi:10.3390/ijms241813955.
Link to cite this reference
This item is licensed under a Creative Commons License